1. Home
  2. BXP vs VTRS Comparison

BXP vs VTRS Comparison

Compare BXP & VTRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • BXP
  • VTRS
  • Stock Information
  • Founded
  • BXP 1970
  • VTRS 1961
  • Country
  • BXP United States
  • VTRS United States
  • Employees
  • BXP N/A
  • VTRS N/A
  • Industry
  • BXP Real Estate Investment Trusts
  • VTRS Medicinal Chemicals and Botanical Products
  • Sector
  • BXP Real Estate
  • VTRS Health Care
  • Exchange
  • BXP Nasdaq
  • VTRS Nasdaq
  • Market Cap
  • BXP 11.4B
  • VTRS 12.2B
  • IPO Year
  • BXP 1997
  • VTRS N/A
  • Fundamental
  • Price
  • BXP $70.72
  • VTRS $10.76
  • Analyst Decision
  • BXP Buy
  • VTRS Hold
  • Analyst Count
  • BXP 17
  • VTRS 6
  • Target Price
  • BXP $77.88
  • VTRS $11.17
  • AVG Volume (30 Days)
  • BXP 1.7M
  • VTRS 9.4M
  • Earning Date
  • BXP 10-28-2025
  • VTRS 11-06-2025
  • Dividend Yield
  • BXP 3.96%
  • VTRS 4.48%
  • EPS Growth
  • BXP N/A
  • VTRS N/A
  • EPS
  • BXP N/A
  • VTRS N/A
  • Revenue
  • BXP $3,425,025,000.00
  • VTRS $14,124,400,000.00
  • Revenue This Year
  • BXP $2.83
  • VTRS N/A
  • Revenue Next Year
  • BXP $2.27
  • VTRS $1.61
  • P/E Ratio
  • BXP N/A
  • VTRS N/A
  • Revenue Growth
  • BXP 2.42
  • VTRS N/A
  • 52 Week Low
  • BXP $54.22
  • VTRS $6.85
  • 52 Week High
  • BXP $84.75
  • VTRS $13.55
  • Technical
  • Relative Strength Index (RSI)
  • BXP 45.60
  • VTRS 57.42
  • Support Level
  • BXP $68.01
  • VTRS $9.92
  • Resistance Level
  • BXP $73.03
  • VTRS $11.28
  • Average True Range (ATR)
  • BXP 1.73
  • VTRS 0.35
  • MACD
  • BXP 0.02
  • VTRS 0.04
  • Stochastic Oscillator
  • BXP 40.31
  • VTRS 61.43

About BXP Boston Properties Inc.

BXP Inc. owns over 180 properties consisting of approximately 53 million rentable square feet of space. The portfolio is dominated by office buildings and is spread across major cities such as New York, Boston, San Francisco, Los Angeles, Seattle, and the Washington, D.C., region. The real estate investment trust also owns limited retail, hotel, and residential properties.

About VTRS Viatris Inc.

Viatris was formed in November 2020 through the combination of Upjohn, a wholly owned subsidiary of Pfizer that specialized in off-patent drugs, and Mylan, a global pharmaceutical manufacturer that focused on generic and specialty drugs. By joining forces, Viatris became one of the largest generic drug manufacturers in the world, servicing over 165 countries. Generics (commoditized and complex) and biosimilars make up roughly 40% of Viatris' total sales. The remaining 60% of sales are derived from its portfolio of legacy products, which includes Lipitor, Norvasc, Lyrica, and Viagra. While it covers more than 10 major therapeutic areas, Viatris has identified dermatology, ophthalmology, and gastroenterology as its three key areas of focus for future innovations.

Share on Social Networks: